EPAS1 and COVID-19: In patients with mild and moderate COVID-19, HIF-2α expression increased the most (6-fold and 10.6-fold relative to controls), followed by HIF-1α (4.3-fold and 8.2-fold), and to a lesser extent, HIF-3α (6.2-fold and 7.1-fold).